Highlights
- Market Cap
- $4.05M
- Enterprise Value
- -$5.85M
- EPS (TTM)
- -$22.73
- Gross Profit (TTM)
- -$46.46K
- EBITDA (TTM)
- -$31.62M
- Year Range
- $1.77 - $9.50
- ROA (TTM)
- -41.53%
- ROE (TTM)
- -49.37%
Share Price Chart
Loading graphics...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
Performance Chart
The chart shows the growth of an initial investment of $10,000 in Dogwood Therapeutics, Inc, comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.
Loading graphics...
Returns By Period
Dogwood Therapeutics, Inc (DWTX) has returned -49.28% so far this year and -57.88% over the past 12 months.
Dogwood Therapeutics, Inc
- 1D
- 18.54%
- 1M
- -25.96%
- YTD
- -49.28%
- 6M
- -72.60%
- 1Y
- -57.88%
- 3Y*
- -38.76%
- 5Y*
- -56.98%
- 10Y*
- —
Benchmark (S&P 500 Index)
- 1D
- 2.91%
- 1M
- -5.09%
- YTD
- -4.63%
- 6M
- -2.39%
- 1Y
- 16.33%
- 3Y*
- 16.69%
- 5Y*
- 10.18%
- 10Y*
- 12.16%
Monthly Returns
Based on dividend-adjusted daily data since Dec 17, 2020, DWTX's average daily return is +0.18%, while the average monthly return is +3.20%. At this rate, your investment would double in approximately 1.8 years.
Historically, 41% of months were positive and 59% were negative. The best month was Jan 2025 with a return of +401.6%, while the worst month was Sep 2022 at -94.6%. The longest winning streak lasted 3 consecutive months, and the longest losing streak was 6 months.
On a daily basis, DWTX closed higher 46% of trading days. The best single day was Jan 23, 2025 with a return of +376.8%, while the worst single day was Sep 19, 2022 at -77.2%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -32.93% | 2.15% | -25.96% | -49.28% | |||||||||
| 2025 | 401.61% | -61.65% | 4.59% | 9.38% | -5.47% | -7.92% | 1.36% | 2.59% | 55.24% | -19.35% | 4.99% | -36.20% | 67.07% |
| 2024 | -28.70% | -9.51% | 29.14% | -5.67% | -52.38% | -0.09% | -1.86% | -8.06% | -12.37% | 2.35% | -44.83% | 3.75% | -82.68% |
| 2023 | 30.76% | -2.79% | 22.50% | 98.64% | 135.62% | -19.77% | 37.68% | -42.11% | -15.93% | -40.53% | 3.45% | 1.05% | 143.64% |
| 2022 | 25.12% | -11.56% | -20.85% | -10.49% | 6.98% | -1.40% | 65.48% | 0.93% | -94.61% | -27.73% | 5.45% | -18.62% | -95.39% |
| 2021 | -9.59% | -8.84% | -7.43% | -5.58% | -2.96% | 19.81% | -5.41% | -14.96% | 4.55% | -11.72% | 16.70% | -6.15% | -31.89% |
Benchmark Metrics
Dogwood Therapeutics, Inc has an annualized alpha of 43.03%, beta of 0.87, and R² of 0.00 versus S&P 500 Index. Calculated based on daily prices since December 18, 2020.
- This stock participated in 260.47% of S&P 500 Index downside but only 35.07% of its upside — more exposed to losses than it benefited from rallies.
- R² of 0.00 means this stock moves largely independently of S&P 500 Index — capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- 43.03%
- Beta
- 0.87
- R²
- 0.00
- Upside Capture
- 35.07%
- Downside Capture
- 260.47%
Return for Risk
Risk / Return Rank
DWTX ranks 14 for risk / return — in the bottom 14% of stocks on our site. This means you're taking on significantly more risk than the returns justify. Consider whether the potential upside is worth the volatility, or explore alternatives with better risk / return profiles.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for Dogwood Therapeutics, Inc (DWTX) and compare them to a chosen benchmark (S&P 500 Index).
| DWTX | Benchmark | Difference | |
|---|---|---|---|
Sharpe ratioReturn per unit of total volatility | -0.54 | 0.90 | -1.43 |
Sortino ratioReturn per unit of downside risk | -0.45 | 1.39 | -1.83 |
Omega ratioGain probability vs. loss probability | 0.95 | 1.21 | -0.27 |
Calmar ratioReturn relative to maximum drawdown | -0.81 | 1.40 | -2.21 |
Martin ratioReturn relative to average drawdown | -1.74 | 6.61 | -8.35 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Explore DWTX risk-adjusted metrics in detail
Dive deeper into individual metrics with historical trends, benchmark comparisons, and performance across different time periods.
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading graphics...
Worst Drawdowns
The table below displays the maximum drawdowns of the Dogwood Therapeutics, Inc. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Dogwood Therapeutics, Inc was 99.57%, occurring on Mar 30, 2026. The portfolio has not yet recovered.
The current Dogwood Therapeutics, Inc drawdown is 99.49%.
Depth | Start | To Bottom | Bottom | To Recover | End | Total |
|---|---|---|---|---|---|---|
| -99.57% | Dec 18, 2020 | 1324 | Mar 30, 2026 | — | — | — |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading graphics...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Dogwood Therapeutics, Inc over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Dogwood Therapeutics, Inc is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |